

# Rosa Ventura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3072294/publications.pdf>

Version: 2024-02-01

156  
papers

4,533  
citations

101543

36  
h-index

149698

56  
g-index

157  
all docs

157  
docs citations

157  
times ranked

3777  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple headspace solid-phase microextraction (MHS-SPME) methodology applied to the determination of volatile metabolites of plasticizers in human urine. <i>Microchemical Journal</i> , 2022, 180, 107567.	4.5	4
2	Elimination profiles of betamethasone after different administration routes: Evaluation of the reporting level and washout periods to ensure safe therapeutic administrations. <i>Drug Testing and Analysis</i> , 2021, 13, 348-359.	2.6	7
3	Elimination profiles of prednisone and prednisolone after different administration routes: Evaluation of the reporting level and washout periods to ensure safe therapeutic administrations. <i>Drug Testing and Analysis</i> , 2021, 13, 571-582.	2.6	10
4	A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes. <i>British Journal of Sports Medicine</i> , 2021, 55, 631-642.	6.7	14
5	Budesonide use and misuse in sports: Elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations. <i>Drug Testing and Analysis</i> , 2020, 12, 629-636.	2.6	11
6	If you play with fire, you may get burned. <i>Drug Testing and Analysis</i> , 2020, 12, 582-587.	2.6	3
7	Analysis of hydroxylated phenylalkylamine stimulants in urine by GC-APPI-HRMS. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 7837-7850.	3.7	4
8	Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. <i>Journal of Chromatography A</i> , 2020, 1631, 461548.	3.7	7
9	Additional studies on triamcinolone acetonide use and misuse in sports: Elimination profile after intranasal and high-dose intramuscular administrations. <i>Steroids</i> , 2019, 151, 108464.	1.8	16
10	Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration. <i>Drug Testing and Analysis</i> , 2019, 11, 1589-1600.	2.6	11
11	Evaluation of sulfate metabolites as markers of intramuscular testosterone administration in Caucasian and Asian populations. <i>Drug Testing and Analysis</i> , 2019, 11, 1218-1230.	2.6	19
12	Sulfate metabolites improve retrospectivity after oral testosterone administration. <i>Drug Testing and Analysis</i> , 2019, 11, 392-402.	2.6	20
13	New approach based on immunochemical techniques for monitoring of selective estrogen receptor modulators (SERMs) in human urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 156, 147-152.	2.8	3
14	The effect of tea consumption on the steroid profile. <i>Drug Testing and Analysis</i> , 2018, 10, 1438-1447.	2.6	5
15	Effect of glucocorticoid administration on the steroid profile. <i>Drug Testing and Analysis</i> , 2018, 10, 947-955.	2.6	11
16	Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part II: Intramuscular administration. <i>Drug Testing and Analysis</i> , 2018, 10, 849-859.	2.6	12
17	Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part I: Transdermal administration. <i>Drug Testing and Analysis</i> , 2018, 10, 821-831.	2.6	16
18	Direct quantitation of endogenous steroid sulfates in human urine by liquid chromatography-electrospray tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2018, 10, 1734-1743.	2.6	27

#	ARTICLE	IF	CITATIONS
19	Detection of erythropoiesis-stimulating agents in a single dried blood spot. <i>Drug Testing and Analysis</i> , 2018, 10, 1496-1507.	2.6	25
20	Evaluation of two glucuronides resistant to enzymatic hydrolysis as markers of testosterone oral administration. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 212-218.	2.5	25
21	LC-MS/MS detection of unaltered glucuroconjugated metabolites of metandienone. <i>Drug Testing and Analysis</i> , 2017, 9, 534-544.	2.6	8
22	Evaluation of uncertainty sources in the determination of testosterone in urine by calibration-based and isotope dilution quantification using ultra high performance liquid chromatography tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2017, 1508, 73-80.	3.7	10
23	Quantifying endogenous androgens, estrogens, pregnenolone and progesterone metabolites in human urine by gas chromatography tandem mass spectrometry. <i>Talanta</i> , 2017, 169, 20-29.	5.5	40
24	Constant Ion Loss Method for the Untargeted Detection of Bis-sulfate Metabolites. <i>Analytical Chemistry</i> , 2017, 89, 1602-1609.	6.5	31
25	Ionization and collision induced dissociation of steroid bisglucuronides. <i>Journal of Mass Spectrometry</i> , 2017, 52, 759-769.	1.6	5
26	Corrigendum to "Genetic and protein biomarkers in blood for the improved detection of GH abuse". <i>J. Pharm. Biomed. Anal.</i> 128 (2016) 111-118, doi: 10.1016/j.jpba.2016.05.022.]. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 134, 385.	2.8	0
27	Evaluation of fibronectin 1 in one dried blood spot and in urine after rhGH treatment. <i>Drug Testing and Analysis</i> , 2017, 9, 1011-1016.	2.6	15
28	Detection of stanozolol and sulfate metabolites and their evaluation as additional markers in doping control. <i>Drug Testing and Analysis</i> , 2017, 9, 1001-1010.	2.6	17
29	Sulfate metabolites as alternative markers for the detection of 4-chlorometandienone misuse in doping control. <i>Drug Testing and Analysis</i> , 2017, 9, 983-993.	2.6	12
30	Exposure to Bisphenol A and Phthalates during Pregnancy and Ultrasound Measures of Fetal Growth in the INMA-Sabadell Cohort. <i>Environmental Health Perspectives</i> , 2016, 124, 521-528.	6.0	119
31	Genetic and protein biomarkers in blood for the improved detection of GH abuse. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 128, 111-118.	2.8	14
32	High-Resolution Mass Spectrometry in Doping Control. <i>Comprehensive Analytical Chemistry</i> , 2016, , 91-117.	1.3	3
33	Targeting tryptophan and tyrosine metabolism by liquid chromatography tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016, 1434, 91-101.	3.7	72
34	Detection and characterization of clostebol sulfate metabolites in Caucasian population. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1022, 54-63.	2.3	27
35	Bioanalytical techniques in discrimination between therapeutic and abusive use of drugs in sport. <i>Bioanalysis</i> , 2016, 8, 965-980.	1.5	11
36	Potential of atmospheric pressure chemical ionization source in gas chromatography tandem mass spectrometry for the screening of urinary exogenous androgenic anabolic steroids. <i>Analytica Chimica Acta</i> , 2016, 906, 128-138.	5.4	29

#	ARTICLE	IF	CITATIONS
37	Factors affecting urinary excretion of testosterone metabolites conjugated with cysteine. <i>Drug Testing and Analysis</i> , 2016, 8, 110-119.	2.6	7
38	Mass spectrometric characterisation of a condensation product between porphobilinogen and indolyl- $\beta$ -acryloylglycine in urine of patients with acute intermittent porphyria. <i>Journal of Mass Spectrometry</i> , 2015, 50, 929-937.	1.6	1
39	Prenatal Phthalate Exposure and Childhood Growth and Blood Pressure: Evidence from the Spanish INMA-Sabadell Birth Cohort Study. <i>Environmental Health Perspectives</i> , 2015, 123, 1022-1029.	6.0	147
40	Prenatal exposure to bisphenol A and phthalates and childhood respiratory tract infections and allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 370-378.e7.	2.9	203
41	Variability and predictors of urinary phthalate metabolites in Spanish pregnant women. <i>International Journal of Hygiene and Environmental Health</i> , 2015, 218, 220-231.	4.3	108
42	Formation of $\beta$ 1 and $\beta$ 6 testosterone metabolites by human hepatocytes. <i>Steroids</i> , 2015, 95, 66-72.	1.8	7
43	Detection and characterization of betamethasone metabolites in human urine by LC-MS/MS. <i>Drug Testing and Analysis</i> , 2015, 7, 663-672.	2.6	19
44	Screening method for stimulants in urine by UHPLC-MS/MS: identification of isomeric compounds. <i>Drug Testing and Analysis</i> , 2015, 7, 819-830.	2.6	14
45	Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS. <i>Journal of Mass Spectrometry</i> , 2015, 50, 633-642.	1.6	26
46	Prenatal exposure to phthalates and neuropsychological development during childhood. <i>International Journal of Hygiene and Environmental Health</i> , 2015, 218, 550-558.	4.3	87
47	Untargeted Metabolomics in Doping Control: Detection of New Markers of Testosterone Misuse by Ultrahigh Performance Liquid Chromatography Coupled to High-Resolution Mass Spectrometry. <i>Analytical Chemistry</i> , 2015, 87, 8373-8380.	6.5	39
48	Urinary cysteinyl progestogens: Occurrence and origin. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 152, 53-61.	2.5	10
49	Screening for anabolic steroids in sports: Analytical strategy based on the detection of phase I and phase II intact urinary metabolites by liquid chromatography tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2015, 1389, 65-75.	3.7	37
50	Ultra high performance liquid chromatography tandem mass spectrometric detection of glucuronides resistant to enzymatic hydrolysis: Implications to doping control analysis. <i>Analytica Chimica Acta</i> , 2015, 895, 35-44.	5.4	17
51	Pseudoephedrine and circadian rhythm interaction on neuromuscular performance. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2015, 25, e603-12.	2.9	37
52	Synthesis and characterization of $6\beta$ -hydroxyandrosterone and $6\beta$ -hydroxyetiocholanolone conjugated with glucuronic acid. <i>Drug Testing and Analysis</i> , 2015, 7, 247-252.	2.6	10
53	Evaluation of the reporting level to detect triamcinolone acetonide misuse in sports. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 94-102.	2.5	18
54	Detection and characterization of triamcinolone acetonide metabolites in human urine by liquid chromatography/tandem mass spectrometry after intramuscular administration. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1829-1839.	1.5	21

#	ARTICLE	IF	CITATIONS
55	Analytical strategies based on mass spectrometric techniques for the study of steroid metabolism. <i>TrAC - Trends in Analytical Chemistry</i> , 2014, 53, 106-116.	11.4	74
56	Evaluation of urinary excretion of androgens conjugated to cysteine in human pregnancy by mass spectrometry. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 139, 192-200.	2.5	18
57	Investigation of endogenous corticosteroids profiles in human urine based on liquid chromatography tandem mass spectrometry. <i>Analytica Chimica Acta</i> , 2014, 812, 92-104.	5.4	60
58	Mass spectrometric behavior of anabolic androgenic steroids using gas chromatography coupled to atmospheric pressure chemical ionization source. Part I: Ionization. <i>Journal of Mass Spectrometry</i> , 2014, 49, 509-521.	1.6	33
59	Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 54.	2.7	11
60	Detection, synthesis and characterization of metabolites of steroid hormones conjugated with cysteine. <i>Steroids</i> , 2013, 78, 327-336.	1.8	37
61	Urinary profile of methylprednisolone and its metabolites after oral and topical administrations. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 214-221.	2.5	31
62	A new sulphate metabolite as a long-term marker of metandienone misuse. <i>Steroids</i> , 2013, 78, 1245-1253.	1.8	57
63	Alternative long-term markers for the detection of methyltestosterone misuse. <i>Steroids</i> , 2013, 78, 44-52.	1.8	67
64	Use of LC-MS/MS for the Open Detection of Steroid Metabolites Conjugated with Glucuronic Acid. <i>Analytical Chemistry</i> , 2013, 85, 5005-5014.	6.5	93
65	Evaluation of the urinary threshold concentration of formoterol in sports drug testing. <i>Drug Testing and Analysis</i> , 2013, 5, 266-269.	2.6	8
66	Discrimination of Prohibited Oral Use From Authorized Inhaled Treatment of Budesonide in Sports. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 118-128.	2.0	27
67	Current status and bioanalytical challenges in the detection of unknown anabolic androgenic steroids in doping control analysis. <i>Bioanalysis</i> , 2013, 5, 2661-2677.	1.5	16
68	New potential markers for the detection of boldenone misuse. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 132, 239-246.	2.5	59
69	Detection and characterization of urinary metabolites of boldione by LC-MS/MS. Part II: Conjugates with cysteine and N-acetylcysteine. <i>Drug Testing and Analysis</i> , 2012, 4, 786-797.	2.6	15
70	Detection and characterization of urinary metabolites of boldione by LC-MS/MS. Part I: Phase I metabolites excreted free, as glucuronide and sulfate conjugates, and released after alkaline treatment of the urine. <i>Drug Testing and Analysis</i> , 2012, 4, 775-785.	2.6	26
71	Recent developments in MS for small molecules: application to human doping control analysis. <i>Bioanalysis</i> , 2012, 4, 197-212.	1.5	18
72	Determination of five di-(2-ethylhexyl)phthalate metabolites in urine by UPLC-MS/MS, markers of blood transfusion misuse in sports. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 908, 113-121.	2.3	36

#	ARTICLE	IF	CITATIONS
73	Using complementary mass spectrometric approaches for the determination of methylprednisolone metabolites in human urine. <i>Rapid Communications in Mass Spectrometry</i> , 2012, 26, 541-553.	1.5	29
74	Alterations of the erythrocyte membrane proteome and cytoskeleton network during storage – a possible tool to identify autologous blood transfusion. <i>Drug Testing and Analysis</i> , 2012, 4, 882-890.	2.6	17
75	Detection methods for autologous blood doping. <i>Drug Testing and Analysis</i> , 2012, 4, 876-881.	2.6	17
76	Identification of budesonide metabolites in human urine after oral administration. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 404, 325-340.	3.7	37
77	Sensitive and robust method for anabolic agents in human urine by gas chromatography–triple quadrupole mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 897, 85-89.	2.3	24
78	Plasticizers excreted in urine: indication of autologous blood transfusion in sports. <i>Transfusion</i> , 2012, 52, 647-657.	1.6	35
79	Progress in the Removal of Di-[2-Ethylhexyl]-Phthalate as Plasticizer in Blood Bags. <i>Transfusion Medicine Reviews</i> , 2012, 26, 27-37.	2.0	78
80	Alternative markers for the long-term detection of oral testosterone misuse. <i>Steroids</i> , 2011, 76, 1367-1376.	1.8	29
81	Current strategic approaches for the detection of blood doping practices. <i>Forensic Science International</i> , 2011, 213, 42-48.	2.2	9
82	Detection of dihydrotestosterone gel, oral dehydroepiandrosterone, and testosterone gel misuse through the quantification of testosterone metabolites released after alkaline treatment. <i>Drug Testing and Analysis</i> , 2011, 3, 828-835.	2.6	31
83	Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 517-528.	3.7	36
84	Response to Letter to the Editor regarding –Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing–. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 579-580.	3.7	2
85	Comparison between triple quadrupole, time of flight and hybrid quadrupole time of flight analysers coupled to liquid chromatography for the detection of anabolic steroids in doping control analysis. <i>Analitica Chimica Acta</i> , 2011, 684, 107-120.	5.4	46
86	Mass spectrometric characterization of urinary toremifene metabolites for doping control analyses. <i>Journal of Chromatography A</i> , 2011, 1218, 4727-4737.	3.7	23
87	Quantification of testosterone and metabolites released after alkaline treatment in human urine. <i>Drug Testing and Analysis</i> , 2010, 2, 630-636.	2.6	21
88	Identification of free and conjugated metabolites of mesocarb in human urine by LC-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 2903-2916.	3.7	12
89	Testosterone metabolism revisited: discovery of new metabolites. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 1759-1770.	3.7	43
90	Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: Immunoassay-based measurement in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 53, 1003-1010.	2.8	12

#	ARTICLE	IF	CITATIONS
91	Enzyme-linked immunosorbent assays for doping control of 5 $\alpha$ -reductase inhibitors finasteride and dutasteride. <i>Analytica Chimica Acta</i> , 2010, 671, 70-79.	5.4	9
92	Urinary di-(2-ethylhexyl)phthalate metabolites in athletes as screening measure for illicit blood doping: a comparison study with patients receiving blood transfusion. <i>Transfusion</i> , 2010, 50, 145-149.	1.6	39
93	Enzyme-linked immunosorbent assays for the synthetic steroid gestrinone. <i>Talanta</i> , 2010, 82, 1581-1587.	5.5	9
94	Research Spotlight: Bioanalysis and Analytical Services Research Group at The Municipal Institute for Medical Research IMIM-Hospital del Mar, Spain. <i>Bioanalysis</i> , 2009, 1, 1403-1409.	1.5	0
95	Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. <i>Veterinary Journal</i> , 2009, 181, 299-304.	1.7	29
96	Evaluation of different scan methods for the urinary detection of corticosteroid metabolites by liquid chromatography tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2009, 44, 929-944.	1.6	46
97	Ultrapformance liquid chromatography tandem mass spectrometric method for direct quantification of salbutamol in urine samples in doping control. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 50, 886-890.	2.8	25
98	Plasma buprenorphine concentrations after the application of a 70 $\mu$ g/h transdermal patch in dogs. Preliminary report. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2009, 32, 503-505.	1.3	22
99	Evaluation of immunoassays for the measurement of insulin and C-peptide as indirect biomarkers of insulin misuse in sport: Values in selected population of athletes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 793-799.	2.8	14
100	Stability of Drugs of Abuse in Oral Fluid Collection Devices With Purpose of External Quality Assessment Schemes. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 277-280.	2.0	31
101	Growth Hormone in Sport: Beyond Beijing 2008. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 3-13.	2.0	23
102	Masking and Manipulation. <i>Handbook of Experimental Pharmacology</i> , 2009, , 327-354.	1.8	9
103	Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 844-852.	2.8	15
104	ORALVEQ: External quality assessment scheme of drugs of abuse in oral fluid. <i>Forensic Science International</i> , 2008, 182, 35-40.	2.2	9
105	Detection of the administration of 17 $\alpha$ -nortestosterone in boars by gas chromatography/mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 1863-1870.	1.5	16
106	Urinary metabolic profile of 19 $\alpha$ -nosteroids in humans: glucuronide and sulphate conjugates after oral administration of 19 $\alpha$ -nor $\Delta^4$ -androstenediol. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 3035-3042.	1.5	29
107	Can glycans unveil the origin of glycoprotein hormones? "human chorionic gonadotrophin as an example". <i>Journal of Mass Spectrometry</i> , 2008, 43, 936-948.	1.6	13
108	Clarification on the detection of epoetin delta and epoetin omega using isoelectric focusing. <i>American Journal of Hematology</i> , 2008, 83, 754-754.	4.1	8

#	ARTICLE	IF	CITATIONS
109	HAIRVEQ 2006: Evolution of laboratories'™ performance after different educational actions. <i>Forensic Science International</i> , 2008, 176, 2-8.	2.2	8
110	Gas chromatography–mass spectrometry method for the analysis of 19-nor-4-androstenediol and metabolites in human plasma: Application to pharmacokinetic studies after oral administration of a prohormone supplement. <i>Steroids</i> , 2008, 73, 751-759.	1.8	10
111	Qualitative evaluation of chromatographic data from quality control schemes using a support vector machine. <i>Analyst</i> , 2008, 133, 105-111.	3.5	2
112	Chapter 21 Doping substances in human and animal sport. <i>Handbook of Analytical Separations</i> , 2008, , 699-744.	0.8	4
113	High-Throughput and Sensitive Screening by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry of Diuretics and other Doping Agents. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 191-200.	1.0	63
114	Effect of Physical Fitness and Endurance Exercise on Indirect Biomarkers of Recombinant Erythropoietin Misuse. <i>International Journal of Sports Medicine</i> , 2007, 28, 9-15.	1.7	18
115	Intermittent hypoxia exposure in a hypobaric chamber and erythropoietin abuse interpretation. <i>Journal of Sports Sciences</i> , 2007, 25, 1241-1250.	2.0	11
116	Validation of a Procedure for the Gas Chromatography-Mass Spectrometry Analysis of Cocaine and Metabolites in Pericardial Fluid. <i>Journal of Analytical Toxicology</i> , 2007, 31, 75-80.	2.8	19
117	Four Years' Experience in External Proficiency Testing Programs for Hair Testing of Drugs of Abuse in Italy (HAIRVEQ) and Comparison With the Society of Hair Testing Program in 2005. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 11-19.	2.0	8
118	Stability Studies of Principal Illicit Drugs in Oral Fluid: Preparation of Reference Materials for External Quality Assessment Schemes. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 662-665.	2.0	20
119	Quantitation of 17 $\beta$ -nandrolone metabolites in boar and horse urine by gas chromatography–mass spectrometry. <i>Analytica Chimica Acta</i> , 2007, 586, 184-195.	5.4	32
120	Stability studies of testosterone and epitestosterone glucuronides in urine. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 858-864.	1.5	28
121	Application of pericardial fluid to the analysis of morphine (heroin) and cocaine in forensic toxicology. <i>Forensic Science International</i> , 2006, 164, 168-171.	2.2	23
122	Stability studies of amphetamine and ephedrine derivatives in urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 843, 84-93.	2.3	46
123	Effect of Physical Fitness and Endurance Exercise on Indirect Biomarkers of Recombinant Growth Hormone Misuse: Insulin-Like Growth Factor I and Procollagen Type III Peptide. <i>International Journal of Sports Medicine</i> , 2006, 27, 976-983.	1.7	16
124	Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 75-85.	2.3	30
125	Evaluation of immunoassays for the measurement of soluble transferrin receptor as an indirect biomarker of recombinant human erythropoietin misuse in sport. <i>Journal of Immunological Methods</i> , 2004, 295, 89-99.	1.4	16
126	HAIRVEQ: an external quality control scheme for drugs of abuse analysis in hair. <i>Forensic Science International</i> , 2004, 145, 109-115.	2.2	26



#	ARTICLE	IF	CITATIONS
127	Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 35, 1169-1177.	2.8	26
128	Detection in urine of efaproxiral (RSR13), a potential doping agent, by a routine screening procedure based on methylation followed by gas chromatography/mass spectrometry. <i>Analytica Chimica Acta</i> , 2004, 505, 227-229.	5.4	9
129	Protocols for stability and homogeneity studies of drugs for its application to doping control. <i>Analytica Chimica Acta</i> , 2004, 515, 323-331.	5.4	17
130	Reference materials for analytical toxicology including doping control: freeze-dried urine samples. <i>Analyst, The</i> , 2004, 129, 449-455.	3.5	16
131	Protocols for stability and homogeneity studies of drugs for its application to doping control. <i>Analytica Chimica Acta</i> , 2004, 515, 323-323.	5.4	0
132	Stability studies of selected doping agents in urine: caffeine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 795, 167-177.	2.3	35
133	Validation of qualitative chromatographic methods: strategy in antidoping control laboratories. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 767, 341-351.	2.3	49
134	Quantification of terbutaline in urine by enzyme-linked immunosorbent assay and capillary electrophoresis after oral and inhaled administrations. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 768, 315-324.	2.3	24
135	Quantification of perphenazine in Eurasian otter ( <i>Lutra lutra lutra</i> ) urine samples by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 769, 79-87.	2.3	22
136	Diagnostic evidence for the presence of $\beta_2$ -agonists using two consecutive derivatization procedures and gas chromatography-mass spectrometric analysis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 780, 61-71.	2.3	42
137	Strategies for internal quality control in antidoping analyses. <i>Analytica Chimica Acta</i> , 2002, 460, 289-307.	5.4	18
138	Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2001, 36, 652-657.	1.6	31
139	Derivatization procedures for the detection of $\beta_2$ -agonists by gas chromatographic/mass spectrometric analysis. <i>Journal of Mass Spectrometry</i> , 2000, 35, 1285-1294.	1.6	64
140	Analytical methodology for the detection of $\beta_2$ -agonists in urine by gas chromatography-mass spectrometry for application in doping control. <i>Analytica Chimica Acta</i> , 2000, 418, 79-92.	5.4	55
141	Discrimination of Prohibited Oral Use of Salbutamol from Authorized Inhaled Asthma Treatment. <i>Clinical Chemistry</i> , 2000, 46, 1365-1375.	3.2	65
142	Chapter 15 Doping substances in human and animal sport. <i>Handbook of Analytical Separations</i> , 2000, 2, 531-566.	0.8	5
143	Distinction of Inhaled and Oral Salbutamol by Urine Analysis Using Conventional Screening Procedures for Doping Control. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 277-282.	2.0	43
144	Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. <i>Clinical Chemistry</i> , 2000, 46, 1365-75.	3.2	14

#	ARTICLE	IF	CITATIONS
145	Analytical methodology for enantiomers of salbutamol in human urine for application in doping control. <i>Biomedical Applications</i> , 1999, 723, 173-184.	1.7	53
146	Derivatization procedures for gas chromatographic mass spectrometric determination of xenobiotics in biological samples, with special attention to drugs of abuse and doping agents. <i>Biomedical Applications</i> , 1998, 713, 61-90.	1.7	223
147	Screening Procedure for $\beta$ -Adrenergic Drugs in Sports Drug Testing by Immunological Methods. <i>Journal of Analytical Toxicology</i> , 1998, 22, 127-134.	2.8	26
148	A Partially Automated Pretreatment Module for Routine Analyses for Seventeen Non-Steroid Antiinflammatory Drugs in Race Horses Using Gas Chromatography/Mass Spectrometry. <i>Analytical Chemistry</i> , 1996, 68, 118-123.	6.5	21
149	Detection of non-steroidal anti-inflammatory drugs in equine plasma and urine by gas chromatography-mass spectrometry. <i>Journal of Chromatography A</i> , 1996, 719, 251-264.	3.7	56
150	Detection of diuretic agents in doping control. <i>Biomedical Applications</i> , 1996, 687, 127-144.	1.7	82
151	Fast screening method for diuretics, probenecid and other compounds of doping interest. <i>Journal of Chromatography A</i> , 1993, 655, 233-242.	3.7	50
152	Determination of mesocarb metabolites by high-performance liquid chromatography with UV detection and with mass spectrometry using a particle-beam interface. <i>Journal of Chromatography A</i> , 1993, 647, 203-210.	3.7	23
153	International cooperation in analytical chemistry: experience of antidoping control at the XI Pan American Games. <i>Clinical Chemistry</i> , 1993, 39, 836-845.	3.2	32
154	International cooperation in analytical chemistry: experience of antidoping control at the XI Pan American Games. <i>Clinical Chemistry</i> , 1993, 39, 836-45.	3.2	9
155	Approach to the analysis of diuretics and masking agents by high-performance liquid chromatography mass spectrometry in doping control. <i>Biomedical Applications</i> , 1991, 562, 723-736.	1.7	33
156	Analysis of naltrexone urinary metabolites. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1988, 6, 887-893.	2.8	5